Hyloris Pharmaceuticals Valuation Multiples

Hyloris Pharmaceuticals Overview

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.

Founded

2012

HQ

Employees

14

Website

hyloris.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $17M

EBITDA: ($12M)

EV

$178M

Valuation Multiples

Multiples.vc

Start free trial

Hyloris Pharmaceuticals Financials

Hyloris Pharmaceuticals reported last 12-month revenue of $17M and negative EBITDA of ($12M).

In the same LTM period, Hyloris Pharmaceuticals generated ($12M) in EBITDA losses and had net loss of ($13M).

Hyloris Pharmaceuticals P&L

In the most recent fiscal year, Hyloris Pharmaceuticals reported revenue of $10M and EBITDA of ($7M).

Hyloris Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Hyloris Pharmaceuticals Stock Performance

Hyloris Pharmaceuticals has current market cap of $199M, and enterprise value of $178M.

Hyloris Pharmaceuticals' stock price is $7.09.

Hyloris Pharmaceuticals Valuation Multiples

Hyloris Pharmaceuticals trades at 10.7x EV/Revenue multiple, and (14.4x) EV/EBITDA.

Hyloris Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Hyloris Pharmaceuticals has market cap of $199M and EV of $178M.

Equity research analysts estimate Hyloris Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hyloris Pharmaceuticals has a P/E ratio of (15.3x).

Hyloris Pharmaceuticals Margins & Growth Rates

Hyloris Pharmaceuticals' revenue in the last 12 month grew by 157%.

Hyloris Pharmaceuticals' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.2M for the same period.

Hyloris Pharmaceuticals' rule of 40 is 108% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hyloris Pharmaceuticals' rule of X is 317% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Hyloris Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Hyloris Pharmaceuticals M&A Activity

Hyloris Pharmaceuticals acquired XXX companies to date.

Last acquisition by Hyloris Pharmaceuticals was on XXXXXXXX, XXXXX. Hyloris Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Hyloris Pharmaceuticals Investment Activity

Hyloris Pharmaceuticals invested in XXX companies to date.

Hyloris Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Hyloris Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).